or Try an Advanced Search...

    Technical Analysis for TCBP - TC BioPharm (Holdings) plc

    Grade Last Price % Change Price Change
    F 1.31 -0.76% -0.01
    TCBP closed down 0.76 percent on Friday, November 1, 2024, on 27 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical TCBP trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish -0.76%
    Lizard Bullish Bullish Day Trade Setup -0.76%
    Older End-of-Day Signals for TCBP ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 20 hours ago
    Down 3% about 20 hours ago
    Down 2 % about 20 hours ago
    Possible NR7 about 20 hours ago
    Possible Inside Day about 20 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    TCBP Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Solid Tumors Immune System Immunotherapy Cancer Treatment Cancer Immunotherapy Cell Therapy Acute Myeloid Leukemia Cell Biology Treatment Of Acute Myeloid Leukemia T Cells Immunotherapy Products

    Is TCBP a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 30 TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements
    Oct 28 Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
    Oct 25 TCBP Responds to False Social Media Claim
    Oct 22 TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic
    Oct 3 TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening
    Sep 25 TCBP Announces Site Opening of Guys and St. Thomas Hospital
    Sep 24 TCBP to Present at the 2024 ThinkEquity Conference in NYC
    Sep 20 /C O R R E C T I O N -- TC BioPharm/
    Sep 12 TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial
    Sep 6 TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
    See more TCBP news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 138.0
    52 Week Low 1.1226
    Average Volume 789,441
    200-Day Moving Average 9.81
    50-Day Moving Average 5.00
    20-Day Moving Average 3.47
    10-Day Moving Average 1.79
    Average True Range 0.66
    RSI (14) 25.93
    ADX 31.45
    +DI 11.29
    -DI 39.58
    Chandelier Exit (Long, 3 ATRs) 6.26
    Chandelier Exit (Short, 3 ATRs) 3.11
    Upper Bollinger Bands 6.91
    Lower Bollinger Band 0.04
    Percent B (%b) 0.18
    BandWidth 197.54
    MACD Line -1.19
    MACD Signal Line -0.97
    MACD Histogram -0.2174
    Fundamentals Value
    Market Cap 886.22 Thousand
    Num Shares 677 Thousand
    EPS -71.42
    Price-to-Earnings (P/E) Ratio -0.02
    Price-to-Sales 0.36
    Price-to-Book 0.29
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.48
    Resistance 3 (R3) 1.47 1.42 1.45
    Resistance 2 (R2) 1.42 1.37 1.42 1.44
    Resistance 1 (R1) 1.36 1.35 1.34 1.37 1.43
    Pivot Point 1.31 1.31 1.29 1.31 1.31
    Support 1 (S1) 1.25 1.26 1.23 1.26 1.19
    Support 2 (S2) 1.20 1.24 1.20 1.18
    Support 3 (S3) 1.14 1.20 1.17
    Support 4 (S4) 1.15